BI 1367.1 (R/R)

An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit

Study Treatments

• BI 894999

Inclusion criteria

• Age 18 years or older
• Patients with histologically confirmed DLBCL who have failed or who are not amenable to standard therapies but have an indication for therapy as per investigator's judgement
• ECOG 0-2
• Measurable disease (radiated lesions do not qualify as target lesions)

Exclusion criteria

• Patient is eligible for curative salvage high dose therapy followed by stem cell transplant.
• Primary central nervous system (CNS) lymphoma or known CNS involvement
• Prior allogeneic bone marrow or stem cell transplant
• High-dose therapy with stem cell support <3 months prior to visit 1

Participating sites

• Institut Jules Bordet
• Cliniques Universitaires UCL Saint Luc